A clinical trial to assess efficacy of Angiotensin Receptor Nephrilysin Inhibitor (Sacubitril/Valsartan) in right ventricular systolic dysfunction with normal LV functionâ??

A Prospective Interventional randomized study to assess efficacy of Angiotensin Receptor Nephrilysin Inhibitor (Sacubitril/Valsartan) in right ventricular systolic dysfunction with normal LV functionâ??

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049280

Enrollment

Registered

2023-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I272- Other secondary pulmonary hypertension

Interventions

Intervention1: Sacubitril/Valsartan: starting dose is 50 twice a day orally and depending on blood pressure dose will be titrated upto 200 twice a day and will be given for 3 months Control Intervent

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Right Ventricular systolic dysfunction with Normal Left ventricular systolic function as diagnosed by transthoracic echocardiography parameters such as TAPSE( 25mm Hg), tricuspid annular velocity( 400pg/ml).

Exclusion criteria

Exclusion criteria: 1. Patients with LVEF 2. Pregnancy 3. Severe hepatic impairment (Child. Pugh C) 4. Severe renal imapairment (eGFR • Hypersensitivity to any component of the product • A prior history of angioedema due to an ACEI or ARB

Design outcomes

Primary

Measure	Time frame
Improvement in clinical ie NYHA class and echo parameter ie TAPSE,PASP,RV S,FAC.Timepoint: First at baseline,1 month, then at 3 month	—

Secondary

Measure	Time frame
CV death, Hypotension, total HF hospitalization.Timepoint: CV death, Hypotension, total HF hospitalization over 3 months	—

Countries

India

Contacts

Public ContactDr Viplov Kesarwani

Dr SN Medical College

drrohitmathur@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026